Valar Labs, a California-based TechMed startup that provides AI-powered computational histology AI (CHAI) tests designed to predict cancer therapies, has secured a $22M Series A funding to augment physicians’ capabilities. The funding round was co-led by DCVC and Andreessen Horowitz (a16z) Bio + Health, with the participation from Pear VC. As part of the partnership, Valar Labs will use the new capital to advance its first AI-based diagnostic test to predict response to cancer treatment and expand its focus to other types of cancer.
read more..